What Actually Rebuilds Bone After Menopause, Not Just Calcium

Quick answer: Bone is roughly 90 percent collagen by volume. Calcium is only the mineral that hardens onto that collagen frame. After menopause, the estrogen signal that tells your body to keep building both new bone and new collagen goes quiet, so calcium you take has less and less frame to lock onto, no matter how much of it you swallow. A 2022 human clinical trial found that purified shilajit, working through fulvic acid, restored that signaling and reversed bone loss in postmenopausal women within 24 weeks. Below is the research behind why calcium alone falls short and what actually rebuilds the frame.

The part of the bone story almost no one explains

Ask most women what their bones are made of and the answer comes back in one word. Calcium.

It is not wrong, but it is a small piece of a bigger picture. By volume, bone is roughly 90 percent collagen, the same structural protein that makes up tendons, skin, and cartilage. Collagen forms a flexible protein scaffold, laid down in an organized weave, and calcium is the mineral that mineralizes onto that scaffold and gives it hardness. Take away the frame, and calcium has nothing to hold onto. It does not simply pile up and harden bone on its own.

Most women never hear this part. They hear "get more calcium" for decades, then watch a bone density scan keep sliding anyway, and the natural conclusion is that they did something wrong, or their body is simply failing them. The research points somewhere else. The frame itself was going quiet.

Why the frame goes quiet after menopause

Bone is living tissue. All day, every day, a small amount of old bone is broken down and a small amount of new bone is built back, a process called remodeling. That balance is not automatic. It runs on a signal.

The signal is estrogen. Estrogen tells the cells that build bone, osteoblasts, to keep working. It also plays a role in keeping the body's own collagen production active, including the collagen your bone frame depends on. As long as that signal is steady, the building side of the ledger roughly keeps pace with the breakdown side.

Menopause cuts that signal sharply. As estrogen declines, the instruction to keep building quiets down, and so does the instruction to keep laying new collagen. Bone breakdown does not slow to match, so the balance tips toward loss. This is the mechanism behind the bone density drop that shows up on a DEXA scan in the years after menopause, and it explains something calcium alone cannot fix, because calcium was never the signal. It was only ever the material.

That is also why a woman can be conscientious about her calcium, her vitamin D, and her weight bearing exercise, and still watch her bone density fall. She is not doing too little. She is handing material to a signal that has gone quiet.

The human trial that reversed the trend

In 2022, Pingali and Nutalapati published a randomized, double blind, placebo controlled trial in the journal Phytomedicine, run at Nizam's Institute of Medical Sciences in Hyderabad. Sixty postmenopausal women, all with existing low bone mass, were split into 3 groups. One took a placebo, one took 250 mg of purified shilajit daily, and one took 500 mg daily, and all were tracked with DEXA scans and blood markers over 48 weeks.

The placebo group's bone density kept falling at both the spine and the hip, the expected path after menopause when nothing changes the underlying signal. Both shilajit groups moved the other direction. Density was preserved and then increased from baseline, and every woman in the treatment groups reversed her osteopenia within 24 weeks.

The blood markers explained why. CTX-1, a marker of bone breakdown, fell in the shilajit groups while it rose on placebo. OPG, a signal that protects bone, rose by roughly 57 percent in the 500 mg group, while RANKL, the signal that tells the body to break bone down, fell. In plain terms, the instruction shifted from tear down to protect and build.

Why the density gain traces back to collagen

A separate line of research explains the frame side of the story specifically. In an 8-week human trial, Das and colleagues took tissue biopsies from women before and after taking shilajit and ran genetic analysis on the samples. A cluster of collagen genes, including COL1A1, COL1A2, and COL3A1, were measured with RT-PCR and showed clear upregulation, with the strongest single gene rising more than 5-fold.

Put the 2 studies together and the picture is coherent rather than 2 separate claims stitched together. The estrogen signaling that shilajit's fulvic acid supports appears to reactivate the genes that build the collagen frame, and in the human bone trial, density measurably rose. The frame gets rebuilt, and the mineral has something to lock onto again.

A calcium supplement alone, no matter the dose, cannot do what this trial showed, for the same reason. Calcium was never the limiting piece. The frame was.

Why this differs from the usual bone-loss route

The standard medications for bone loss, drugs like the bisphosphonate class, are antiresorptive. That means they slow the rate at which old bone is broken down. It is a brake, not a builder. The best case on that path is usually losing less, with bone that sits frozen in place, aging and growing more brittle underneath a density number that looks stable.

The shilajit trial showed something a brake cannot do. Density rose from baseline. It is also worth being precise about what this is not. Shilajit is not a hormone and it does not add estrogen to the body. The estrogen signal that tells bone to rebuild had gone quiet after menopause, and shilajit's fulvic acid appears to support that signaling rather than replace a hormone, which is why it can sit alongside the rest of a woman's routine rather than compete with it.

The safety question women ask first

Because estrogen is part of this story, the first question is usually whether shilajit is safe for a woman with a family history of breast cancer. In laboratory research, fulvic acid reduced the viability of MCF-7 and MDA-MB-231 breast cancer cells and pushed them toward programmed cell death, while sparing normal MCF-10A breast cells, the opposite of feeding estrogen sensitive cells. In the Pingali bone trial itself, no woman discontinued due to a side effect, and vitamin D levels did not change in any group, which rules out added vitamin D as the explanation for the bone gains.

That fits the wider record. Across every human clinical study ever done on shilajit, zero serious adverse events have been reported.

Purity is the fair follow up question for any mineral resin. Optimum shilajit comes from the Altai mountains, cold pressed and purified, and every batch is independently tested by a third-party laboratory for heavy metals and mold, and it is Prop 65 compliant in California. It is made by a small, family owned company out of Florida, and a real person answers when you reach out.

What this actually means for you

If you have kept up with calcium, vitamin D, and exercise and watched your bone density fall anyway, the missing piece was never more discipline. It was the signal that tells your body to keep building the frame calcium depends on.

The research shows that signal can be supported again. In a human clinical trial, women past menopause with existing bone loss reversed it within 24 weeks on purified shilajit, and separate tissue research points to the collagen genes coming back on as the reason why. Calcium still matters. It was just never going to be enough by itself.

If you want to give your own bones the signal calcium alone cannot provide, you can find Optimum Shilajit here: https://www.liveoptimum.co/products/optimum-shilajit

References

1. Pingali U, Nutalapati C. Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial. Phytomedicine. 2022;105:154334. https://pubmed.ncbi.nlm.nih.gov/35933897/
2. Das A, et al. Transcriptome analysis of human muscle biopsies following shilajit supplementation reveals upregulation of extracellular matrix and collagen genes. 2016. https://pubmed.ncbi.nlm.nih.gov/27414521/
3. Kangari P, et al. Shilajit accelerates osteogenic differentiation of human adipose-derived stem cells. 2022. https://pubmed.ncbi.nlm.nih.gov/36153551/
4. Rahmani Barouji S, et al. Shilajit (mummy) inhibits breast cancer cell proliferation and induces apoptosis in MCF-7 and MDA-MB-231 cells while sparing normal MCF-10A cells. 2020. https://pubmed.ncbi.nlm.nih.gov/34466597/
5. </content>